Amgen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
Study Evaluating AMG 706 in Subjects With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Tumors
- Interventions
- Drug: Anti-angiogenesisDrug: AMG 706
- First Posted Date
- 2004-10-08
- Last Posted Date
- 2013-05-15
- Lead Sponsor
- Amgen
- Target Recruit Count
- 71
- Registration Number
- NCT00093873
Study of Darbepoetin Alfa for the Treatment of Anemia of Cancer
- First Posted Date
- 2004-09-21
- Last Posted Date
- 2013-05-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 1000
- Registration Number
- NCT00091858
Two Dose Schedules of Panitumumab in Subjects With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- OncologyTumorsSolid Tumors
- Interventions
- First Posted Date
- 2004-09-21
- Last Posted Date
- 2009-07-10
- Lead Sponsor
- Amgen
- Target Recruit Count
- 86
- Registration Number
- NCT00091806
Study of AMG 706 in Subjects With Advanced Gastrointestinal Stromal Tumors (GISTs)
Phase 2
Completed
- Conditions
- Gastrointestinal Cancer
- Interventions
- Drug: AMG 706
- First Posted Date
- 2004-08-20
- Last Posted Date
- 2013-04-29
- Lead Sponsor
- Amgen
- Target Recruit Count
- 138
- Registration Number
- NCT00089960
Combination Chemotherapy in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
Phase 2
- Conditions
- PainProstate Cancer
- First Posted Date
- 2004-06-08
- Last Posted Date
- 2013-12-04
- Lead Sponsor
- Amgen
- Registration Number
- NCT00005960
- Locations
- 🇺🇸
New York Medical College, Valhalla, New York, United States
🇺🇸Arena Oncology Associates, Great Neck, New York, United States
🇺🇸Associates of Hematology/Oncology, Upland, Pennsylvania, United States
Heart Failure and Anemia
Phase 2
Completed
- Conditions
- Heart FailureAnemia
- First Posted Date
- 2002-11-19
- Last Posted Date
- 2009-08-07
- Lead Sponsor
- Amgen
- Target Recruit Count
- 300
- Registration Number
- NCT00049985
Monoclonal Antibody Treatment for Non-Hodgkin's Lymphoma (Low-Grade)
Phase 2
Completed
- Conditions
- Non-Hodgkin's Lymphoma
- First Posted Date
- 2002-09-09
- Last Posted Date
- 2007-12-28
- Lead Sponsor
- Amgen
- Registration Number
- NCT00044902
Recombinant Human Keratinocyte Growth Factor to Reduce Oral Mucositis in Hematologic Malignancy Patients Undergoing Peripheral Blood Stem Cell Transplantation After Radiation and High-dose Chemotherapy
Phase 3
Completed
- Conditions
- Stomatitis
- First Posted Date
- 2002-07-15
- Last Posted Date
- 2013-05-08
- Lead Sponsor
- Amgen
- Registration Number
- NCT00041665
A Study of an Investigational Medication for Severe Primary Hyperparathyroidism or Parathyroid Cancer
Phase 4
Completed
- Conditions
- HyperparathyroidismParathyroid Neoplasms
- First Posted Date
- 2002-05-20
- Last Posted Date
- 2013-05-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 46
- Registration Number
- NCT00037518
© Copyright 2025. All Rights Reserved by MedPath